التفاصيل البيبلوغرافية
| العنوان: |
Nivolumab Plus Ipilimumab in Patients With Solid Tumors With ATM Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. |
| المؤلفون: |
Rohatgi, Nitin, Rothe, Michael, Mangat, Pam K., Garrett-Mayer, Elizabeth, Meric-Bernstam, Funda, Pisick, Evan, Alese, Olatunji B., Reynolds, Christopher M., Thota, Ramya, Vaccaro, Gina M., von Mehren, Margaret, Arend, Rebecca C., Chiu, Vi K., Duvivier, Herbert L., Gold, Philip J., Hack, Keely, Marr, Alissa S., Winer, Arthur, Grantham, Gina N., Hinshaw, Dominique C. |
| المصدر: |
JCO Precision Oncology; 11/1/2023, Vol. 7, p1-11, 11p |
| مصطلحات موضوعية: |
NIVOLUMAB, IPILIMUMAB, CANCER patients, AUTOMATED teller machines, DRUG target |
| مستخلص: |
PURPOSE: The Targeted Agent and Profiling Utilization Registry Study is a phase II basket study evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancers with genomic alterations known to be drug targets. Results of a cohort of patients with solid tumors with ATM mutations treated with nivolumab plus ipilimumab are reported. METHODS: Eligible patients had measurable disease (RECIST v.1.1), Eastern Cooperative Oncology Group performance status 0-2, adequate organ function, and no standard treatment options. Primary end point was disease control (DC), defined as complete (CR) or partial (PR) response or stable disease (SD) of at least 16 weeks duration (SD16+). Low-accruing histology-specific cohorts with ATM mutations treated with nivolumab plus ipilimumab were collapsed into a single histology-pooled cohort for this analysis. The results were evaluated based on a one-sided exact binomial test with a null DC rate of 15% versus 35% (power =.84; α =.10). Secondary end points were objective response (OR), progression-free survival, overall survival, duration of response, duration of SD, and safety. RESULTS: Twenty-nine patients with 10 tumor types with ATM mutations were enrolled from January 2018 to May 2020. One patient was not evaluable for efficacy. One CR, three PR, and three SD16+ were observed for DC and OR rates of 24% (P =.13; one-sided 90% CI: 14 to 100) and 14% (95% CI: 4 to 32), respectively. The null hypothesis of 15% DC rate was not rejected. Eleven patients had one treatment-related grade 3 adverse event (AE) or serious AE. There were two treatment-related patient deaths including immune-related encephalitis and respiratory failure. CONCLUSION: Nivolumab plus ipilimumab did not meet prespecified criteria to declare a signal of activity in patients with solid tumors with ATM mutations. Nivolumab + ipilimumab did not meet @ASCO #TAPUR criteria to declare antitumor activity in patients w/ ATM-mutated solid tumors. [ABSTRACT FROM AUTHOR] |
|
Copyright of JCO Precision Oncology is the property of American Society of Clinical Oncology and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
